1. European Urology Oncology
Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7–10 Prostate Cancer in Biopsy- naïve Men 
Lars Boesen, Nis Nørgaard, Vibeke Løgager, Ingegerd Balslev, Rasmus Bisbjerg, Karen-Cecilie Thestrup, Henrik Jakobsen, Henrik S. Thomsen 
European Urology Oncology 
DOI: /j.euo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Prostate cancer (PCa) detection rates for all patients (N=808) based on combined biopsy results stratified by bpMRI suspicion scores, PSA density, and PCa grade groups. Confirmatory biopsies showed that 7% (21/300) of patients with low-suspicion, 19% (23/124) with equivocal-suspicion, and 62% (239/384) of patients with high-suspicion bpMRI results had significant PCa (sPCa). Of the 283 patients with sPCa, 9% (25/283) had PSAd <0.10, 25% (70/283) had PSAd of 0.10–0.14, 23% (65/283) had PSAd of 0.15–0.19, and 44% (123/283) had PSAd ≥0.20. bpMRI=biparametric magnetic resonance imaging; CBx=combined biopsies [TRUSbx+TBx]; GGG=Gleason grade group; GS=Gleason score; PCa=prostate cancer; PSA=prostate-specific-antigen; PSAd=PSA density (ng/ml/cc); TBx=bpMRI targeted biopsies; TRUSbx=standard transrectal ultrasound-guided biopsies.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

3. Fig. 2
Decision curve analysis for the six best biopsy strategies with the highest net benefit using threshold probabilities ranging from 5% to 20%, which is equivalent to performing biopsies in 20 men for the 5% threshold and in five men for the 20% threshold to find one man with significant prostate cancer (sPCa). The reference strategy was to biopsy all men. The biopsy strategy with the highest net benefit in detecting sPCa at a specific threshold probability had the greatest clinical value. The dotted vertical line indicates a biopsy threshold of 10%, equivalent to performing biopsies in 10 men to find one additional sPCa. bpMRI=biparametric magnetic resonance imaging; PCa=prostate cancer; PSA=prostate-specific-antigen; PSAd=PSA density (ng/ml/cc).
European Urology Oncology DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions